Logo image of COVA

CRESCENT COVE ACQUISITION-A (COVA) Stock Fundamental Analysis

USA - NASDAQ:COVA - KYG2554Y1044 - Common Stock

10.55 USD
+0.27 (+2.63%)
Last: 12/20/2022, 8:21:12 PM
11.79 USD
+1.24 (+11.75%)
After Hours: 12/20/2022, 8:21:12 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to COVA. COVA was compared to 0 industry peers in the Unkown industry. COVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. COVA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

COVA had positive earnings in the past year.
In the past year COVA has reported a negative cash flow from operations.
COVA Yearly Net Income VS EBIT VS OCF VS FCFCOVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 0 2M -2M 4M 6M 8M 10M

1.2 Ratios

Industry RankSector Rank
ROA 3.12%
ROE 3.29%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COVA Yearly ROA, ROE, ROICCOVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 0 -10 -20 -30 -40

1.3 Margins

COVA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COVA Yearly Profit, Operating, Gross MarginsCOVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, COVA has more shares outstanding
There is no outstanding debt for COVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
COVA Yearly Shares OutstandingCOVA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 10M 20M 30M
COVA Yearly Total Debt VS Total AssetsCOVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 100M 200M 300M

2.2 Solvency

An Altman-Z score of 14.89 indicates that COVA is not in any danger for bankruptcy at the moment.
There is no outstanding debt for COVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.89
ROIC/WACCN/A
WACCN/A
COVA Yearly LT Debt VS Equity VS FCFCOVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 0.06 indicates that COVA may have some problems paying its short term obligations.
A Quick Ratio of 0.06 indicates that COVA may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
COVA Yearly Current Assets VS Current LiabilitesCOVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 200K 400K 600K

More info and screens

1

3. Growth

3.1 Past

COVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 110876.75%, which is quite impressive.
EPS 1Y (TTM)110876.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-68.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

COVA is valuated quite expensively with a Price/Earnings ratio of 42.20.
When comparing the Price/Earnings ratio of COVA to the average of the S&P500 Index (27.49), we can say COVA is valued expensively.
Industry RankSector Rank
PE 42.2
Fwd PE N/A
COVA Price Earnings VS Forward Price EarningsCOVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COVA Per share dataCOVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

COVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRESCENT COVE ACQUISITION-A

NASDAQ:COVA (12/20/2022, 8:21:12 PM)

After market: 11.79 +1.24 (+11.75%)

10.55

+0.27 (+2.63%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.08%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap395.63M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 42.2
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.38
P/tB 1.38
EV/EBITDA N/A
EPS(TTM)0.25
EY2.37%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0
BVpS7.64
TBVpS7.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.12%
ROE 3.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z 14.89
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)110876.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-68.41%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18211.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A